Oncologists, Rheumatologists Warn HHS Not To Move Part B Drugs Into Part D

May 17, 2018
Specialists with a big stake in Part B warn HHS that following through with the administration’s proposal to let Part D plans negotiate Part B drug prices would cause patients to face access restrictions in Part D that they don’t have to deal with in Part B. Also, rheumatologists say rheumatoid arthritis drugs listed on the drug spending dashboard are cheaper in Part B than in Part D. Despite strong opposition from both brand drug makers and specialists, HHS Secretary...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.